Developer docs
API playgroundTry for free, no card

Search company profiles

CELONIC

Full company profile

uuid0008oqg

Namestring
CELONIC
Legal namestring
Celonic AG
Websiteurl
celonic.com
Company typeenum
Private
Founded yearint
1982
Descriptiontext

Celonic AG (operating as Celonic Group) is a Switzerland-based, privately held pure-play biologics Contract Development and Manufacturing Organization (CDMO) headquartered in Basel with a GMP manufacturing site in Heidelberg, Germany. The company was founded in 1982 as a spin-off of the Max Planck Institute, acquired by the J.RETTENMAIER & Söhne (JRS Group) in 2011, and now operates with 500+ employees serving small, mid-size, and large biotechnology companies as well as biosimilar developers across the full lifecycle of monoclonal antibodies, bispecifics, and other complex biologics.

Celonic's service portfolio spans preclinical development (cell line development, upstream and downstream process development, analytical method development, and non-GMP pilot manufacturing), clinical supply manufacturing (50L to 1,000L single-use bioreactor scale for IND, Phase II/III campaigns), and late-phase and commercial manufacturing via a 6x2,000L mid-scale single-use bioreactor asset in Heidelberg. The technology stack centers on CHO-based expression, anchored by the proprietary GS-CHOvolution® cell line platform (built on Revvity's CHOSOURCE™ with TnT transposon technology under a royalty-free simplified license), alongside perfusion and process intensification capabilities (N-1 perfusion, full perfusion), Merck's Breez™ micro-bioreactor platform for early-stage perfusion development, and Cytiva's Xcellerex XDR single-use bioreactor systems. Fill and finish is delivered through a third-party strategic alliance partner. The firm markets standard antibody development cycles of under 12 months, downstream processing yields of 65-70%+ of target mAb, and titers up to 8g/L as quantifiable differentiators.

Commercially, Celonic generates revenue through fee-for-service development contracts and multi-year commercial supply agreements negotiated on a project-by-project basis, with no publicly disclosed pricing tiers. The go-to-market is enterprise field sales targeting pharmaceutical and biotech buyers directly, supported by a Basel Biologics Development Center inaugurated in June 2024 and recent strategic moves including a long-term catumaxomab commercial supply agreement with LINDIS Biotech (February 2025) and an ADC strategic alliance with CARBOGEN AMCIS (October 2025). The customer mix spans biotech, biosimilar, and pharma companies with approved therapeutics, and the company operates with EU cGMP certification at Heidelberg under regulatory oversight by Regierungspräsidium Tübingen on behalf of EMA. Celonic is led by CEO Dr. Samanta Cimitan (since August 2023), CFO Alex Villiger, and EVP Operations Hans-Joachim Janhsen.

Short descriptiontext

Celonic is a Switzerland-based, pure-play biologics CDMO offering end-to-end drug substance development and manufacturing services — from cell line development through commercial supply — for monoclonal antibodies, bispecifics, and complex biologics, serving small to large biotech and biosimilar companies from its Basel development center and Heidelberg GMP facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, cell line development, biopharmaceutical CDMO services, monoclonal antibody production, GMP manufacturing services
Industry2 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Celonic provides end-to-end drug substance development and manufacturing solutions for monoclonal antibodies, bispecifics, and other complex molecules, ranging from Cell Line Development to Commercial Manufacturing. Revenue is generated through fee-for-service contracts for preclinical, clinical, and commercial manufacturing projects. Fill and Finish is offered via a third-party strategic alliance partner.

celonic.com
2Commercial Manufacturing Supply Agreement
TypeManaged Services
Description

Long-term multi-year manufacturing service agreements for commercial supply of approved biologics, such as the catumaxomab agreement with LINDIS Biotech. Revenue derived from commercial manufacturing at GMP facilities.

celonic.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Pricing details1 tier
1Project-based pricing for CDMO services tailored to client requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Fee-for-service model with pricing based on specific project scope, phase (preclinical, clinical, commercial), molecule complexity, bioreactor scale (50L to 2000L), and service requirements. No public pricing tiers available.

celonic.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1GS-CHOvolution®
Description

Gene-edited Glutamine Synthetase (GS) knockout CHO K1 cGMP-compliant cell line expression system with TnT transposon technology for accelerated cell line development

celonic.com
Core offering1 text field

Celonic Group is a pure-play Biologics Contract Development and Manufacturing Organization (CDMO) offering end-to-end drug substance development and manufacturing solutions for monoclonal antibodies, bispecifics, and other complex molecules. Services span from cell line development and preclinical process development through clinical GMP manufacturing to late-phase and commercial supply, leveraging proprietary GS-CHOvolution® cell line technology, perfusion-based bioprocessing, and integrated ADC development through strategic alliance with CARBOGEN AMCIS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Standard Antibody development from Gene to Drug Product in less than 12 months
+4 more records
Product overview1 text field

Celonic Group is a Pure Play Biologics Contract Development and Manufacturing Organization (CDMO) offering end-to-end drug substance development and manufacturing solutions. The portfolio includes the GS-CHOvolution cell line expression system for cell line development, perfusion-based bioprocessing technologies (N-1 perfusion and full perfusion) for process intensification, and integrated ADC development and manufacturing through the CARBOGEN AMCIS strategic alliance. Service offerings span preclinical/early phase development, clinical supply manufacturing (50L-1000L), and late-phase/commercial manufacturing (6x2000L mid-scale). Fill and finish services are offered via third-party strategic alliance partner.

Product and service6 records
1GS-CHOvolution Cell Line Expression System
CategoryPlatform Technology
Description

Gene-edited Glutamine Synthetase (GS) knockout CHO-K1 cGMP-compliant cell line expression system using TnT transposon technology for accelerated cell line development. Based on Revvity's CHOSOURCE platform, suitable for monoclonal antibodies, bispecifics, and complex proteins with high-expressing clone selection and simplified royalty-free licensing.

2ADC Development and Manufacturing Platform
CategoryIntegrated Service Platform
Description

Fully integrated antibody-drug conjugate (ADC) development and manufacturing solution offered through strategic alliance with CARBOGEN AMCIS. Covers cell line development, antibody production, payload/linker synthesis, conjugation, and sterile fill-finish from DNA to drug product. Designed for ADC innovators from early-stage development through commercial launch.

3Preclinical Services
CategoryService
Description

Early-phase development services including cell line development, upstream (USP) and downstream (DSP) process development, analytical method development, and pilot-scale manufacturing for non-GMP tox material generation. Supports fed-batch, N-1 perfusion, and full perfusion processes up to Pilot Scale (200L Non-GMP).

4Clinical Supply Manufacturing
CategoryService
Description

Clinical GMP manufacturing services using small-scale asset with 50L, 200L, and 1000L single-use bioreactors. Supports fed-batch, N-1 perfusion, and full perfusion processes for IND, Phase II resupply, and Phase III PPQ.

5Late Phase and Commercial Manufacturing
CategoryService
Description

Commercial GMP manufacturing services leveraging 6x2000L mid-scale asset for scale-up and scale-out production. Supports late-phase clinical through commercial supply with process transfer and PPQ capabilities.

6Perfusion-Based Bioprocessing
CategoryTechnology Platform
Description

Next-generation bioprocessing technology involving continuous exchange of fresh medium for spent medium while retaining cells. Includes N-1 perfusion (intensified fed-batch) and full perfusion. Enables higher cell densities, higher titers, and lower cost of goods per gram with improved sustainability versus stainless steel processes.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

Celonic Group and CARBOGEN AMCIS formed a strategic alliance to offer a fully integrated ADC development and manufacturing solution. The partnership combines Celonic's advanced biologics capabilities (cell line development and antibody production) with CARBOGEN AMCIS's expertise in payload synthesis, conjugation, and sterile fill-finish. This creates a seamless, end-to-end platform for ADC innovators from DNA to drug product. The alliance aims to streamline supply chain, speed up timelines, and support clients from early-stage development through commercial launch.

2Merck ( Darmstadt, Germany)
Strategic tierKeyTypeTechnology or IntegrationAnnounced on2025-03-12
Description

Celonic Group is integrating Merck's Breez™ micro-bioreactor platform into its process development. The Breez™ 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture system. This addition enhances Celonic's capabilities in monoclonal antibody development and manufacturing by enabling highly efficient, scalable perfusion-based bioprocessing.

celonic.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-19
Description

Celonic Group signed a long-term multi-year manufacturing service agreement with LINDIS Biotech for the commercial supply of catumaxomab, a first-in-class trifunctional bispecific monoclonal antibody approved by EMA for treatment of malignant ascites. Celonic will manufacture catumaxomab at its state-of-the-art GMP facility in Heidelberg, Germany.

Strategic tierKeyTypeTechnology or IntegrationAnnounced on2024-06-18
Description

Celonic's new Biologics Development Center in Basel features Cytiva's Xcellerex XDR single-use bioreactor system. The Xcellerex XDR Bioreactor is a robust and flexible system that can scale from process development to manufacturing scale, enabling customers to reach clinical and commercial milestones faster.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-04-08
Description

Celonic signed a commercial license agreement with Revvity for its CHOSOURCE™ expression platform and TnT transposon technology. The Revvity expression platform is used in combination with Celonic's expertise and workflows to enhance cell line development of monoclonal antibodies and complex proteins. Revvity's cGMP manufacturing CHO cell line has over 65 INDs filed globally.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

World's largest pure-play biologics CDMO with end-to-end mammalian and microbial manufacturing services. Direct competitor to Celonic in mAb, bispecific, and biosimilar development and commercial manufacturing; notably, Celonic's CEO Dr. Samanta Cimitan previously led Lonza Group Operations Strategy.

TypeDirect peer
Description

Global pure-play biologics CDMO with mammalian and microbial capabilities across multiple sites in Europe, U.S., and Asia. Direct competitor offering similar end-to-end services including cell line development, process intensification, and commercial manufacturing.

TypeDirect peer
Description

Privately held European pure-play biologics CDMO headquartered in Germany with similar scale and end-to-end mammalian cell culture services from cell line to commercial supply. Closest comparable in size, ownership structure, and customer focus.

TypeDirect peer
Description

Major global biologics CDMO with integrated discovery, development, and manufacturing services across China, Ireland, and the U.S. Direct competitor across the full biologics CDMO value chain.

TypeDirect peer
Description

European-based biologics CDMO with cell line development, process development, and GMP manufacturing for biosimilars and novel biologics. Direct competitor in the mid-sized European biologics CDMO segment; Celonic's CFO previously held a role at Polpharma Biologics.

TypeDirect peer
Description

One of the world's largest biologics CDMOs by capacity, operating mega-scale commercial manufacturing plants in South Korea. Direct competitor for large-molecule mAb commercial supply where Celonic's mid-scale asset is structurally sub-scale.

TypeBroad incumbent
Description

Large multi-modality CDMO (biologics, cell therapy, oral and injectable fill-finish) recently taken private by Novo Holdings. Broader portfolio than Celonic but overlapping in biologics drug substance and fill-finish — overlapping less on mAb focus but serving similar biopharma clients.

TypeDirect peer
Description

Global biologics CDMO with extensive mammalian and microbial manufacturing capacity across the U.S., U.K., and Denmark. Direct competitor for large-molecule commercial supply and process intensification programs.

TypeBroad incumbent
Description

Diversified life sciences giant with a large contract manufacturing and clinical services business (Patheon). Overlaps with Celonic on biologics development and commercial manufacturing but as part of a much broader portfolio spanning small molecules, clinical research, and lab services.

10Boehringer Ingelheim BioXcellence
TypeDirect peer
Description

Biologics CDMO business of Boehringer Ingelheim offering mammalian cell culture contract manufacturing from clinical to commercial supply. Direct competitor in the European biologics CDMO segment with larger commercial capacity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CELONIC

Biopharmaceutical CDMO Servicescelonic.com

Celonic is a Switzerland-based, pure-play biologics CDMO offering end-to-end drug substance development and manufacturing services — from cell line development through commercial supply — for monoclonal antibodies, bispecifics, and complex biologics, serving small to large biotech and biosimilar companies from its Basel development center and Heidelberg GMP facility.

What CELONIC does

Celonic AG (operating as Celonic Group) is a Switzerland-based, privately held pure-play biologics Contract Development and Manufacturing Organization (CDMO) headquartered in Basel with a GMP manufacturing site in Heidelberg, Germany. The company was founded in 1982 as a spin-off of the Max Planck Institute, acquired by the J.RETTENMAIER & Söhne (JRS Group) in 2011, and now operates with 500+ employees serving small, mid-size, and large biotechnology companies as well as biosimilar developers across the full lifecycle of monoclonal antibodies, bispecifics, and other complex biologics.

Celonic's service portfolio spans preclinical development (cell line development, upstream and downstream process development, analytical method development, and non-GMP pilot manufacturing), clinical supply manufacturing (50L to 1,000L single-use bioreactor scale for IND, Phase II/III campaigns), and late-phase and commercial manufacturing via a 6x2,000L mid-scale single-use bioreactor asset in Heidelberg. The technology stack centers on CHO-based expression, anchored by the proprietary GS-CHOvolution® cell line platform (built on Revvity's CHOSOURCE™ with TnT transposon technology under a royalty-free simplified license), alongside perfusion and process intensification capabilities (N-1 perfusion, full perfusion), Merck's Breez™ micro-bioreactor platform for early-stage perfusion development, and Cytiva's Xcellerex XDR single-use bioreactor systems. Fill and finish is delivered through a third-party strategic alliance partner. The firm markets standard antibody development cycles of under 12 months, downstream processing yields of 65-70%+ of target mAb, and titers up to 8g/L as quantifiable differentiators.

Commercially, Celonic generates revenue through fee-for-service development contracts and multi-year commercial supply agreements negotiated on a project-by-project basis, with no publicly disclosed pricing tiers. The go-to-market is enterprise field sales targeting pharmaceutical and biotech buyers directly, supported by a Basel Biologics Development Center inaugurated in June 2024 and recent strategic moves including a long-term catumaxomab commercial supply agreement with LINDIS Biotech (February 2025) and an ADC strategic alliance with CARBOGEN AMCIS (October 2025). The customer mix spans biotech, biosimilar, and pharma companies with approved therapeutics, and the company operates with EU cGMP certification at Heidelberg under regulatory oversight by Regierungspräsidium Tübingen on behalf of EMA. Celonic is led by CEO Dr. Samanta Cimitan (since August 2023), CFO Alex Villiger, and EVP Operations Hans-Joachim Janhsen.

CELONIC firmographics

Firmographics
Name
CELONIC
Legal name
Celonic AG
Website
https://celonic.com
Company type
Private
Founded year
1982
Operating status
Operating
Headcount range
251–500 employees
Short description
Celonic is a Switzerland-based, pure-play biologics CDMO offering end-to-end drug substance development and manufacturing services — from cell line development through commercial supply — for monoclonal antibodies, bispecifics, and complex biologics, serving small to large biotech and biosimilar companies from its Basel development center and Heidelberg GMP facility.
Ownership category
akta.pro rank

CELONIC industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Biologics contract manufacturing
  • Cell line development
  • Biopharmaceutical CDMO services
  • Monoclonal antibody production
  • GMP manufacturing services

Where CELONIC is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

CELONIC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services: Celonic provides end-to-end drug substance development and manufacturing solutions for monoclonal antibodies, bispecifics, and other complex molecules, ranging from Cell Line Development to Commercial Manufacturing. Revenue is generated through fee-for-service contracts for preclinical, clinical, and commercial manufacturing projects. Fill and Finish is offered via a third-party strategic alliance partner.
  2. Commercial Manufacturing Supply Agreement: Long-term multi-year manufacturing service agreements for commercial supply of approved biologics, such as the catumaxomab agreement with LINDIS Biotech. Revenue derived from commercial manufacturing at GMP facilities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based pricing for CDMO services tailored to client requirements

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

CELONIC product offering

Product offering

Core offering

Celonic Group is a pure-play Biologics Contract Development and Manufacturing Organization (CDMO) offering end-to-end drug substance development and manufacturing solutions for monoclonal antibodies, bispecifics, and other complex molecules. Services span from cell line development and preclinical process development through clinical GMP manufacturing to late-phase and commercial supply, leveraging proprietary GS-CHOvolution® cell line technology, perfusion-based bioprocessing, and integrated ADC development through strategic alliance with CARBOGEN AMCIS.

Product overview

Celonic Group is a Pure Play Biologics Contract Development and Manufacturing Organization (CDMO) offering end-to-end drug substance development and manufacturing solutions. The portfolio includes the GS-CHOvolution cell line expression system for cell line development, perfusion-based bioprocessing technologies (N-1 perfusion and full perfusion) for process intensification, and integrated ADC development and manufacturing through the CARBOGEN AMCIS strategic alliance. Service offerings span preclinical/early phase development, clinical supply manufacturing (50L-1000L), and late-phase/commercial manufacturing (6x2000L mid-scale). Fill and finish services are offered via third-party strategic alliance partner.

Differentiator

Problem solved

Functional benefit

Brands

  • GS-CHOvolution®: Gene-edited Glutamine Synthetase (GS) knockout CHO K1 cGMP-compliant cell line expression system with TnT transposon technology for accelerated cell line development

Products and services

  • GS-CHOvolution Cell Line Expression System Gene-edited Glutamine Synthetase (GS) knockout CHO-K1 cGMP-compliant cell line expression system using TnT transposon technology for accelerated cell line development. Based on Revvity's CHOSOURCE platform, suitable for monoclonal antibodies, bispecifics, and complex proteins with high-expressing clone selection and simplified royalty-free licensing.
  • ADC Development and Manufacturing Platform Fully integrated antibody-drug conjugate (ADC) development and manufacturing solution offered through strategic alliance with CARBOGEN AMCIS. Covers cell line development, antibody production, payload/linker synthesis, conjugation, and sterile fill-finish from DNA to drug product. Designed for ADC innovators from early-stage development through commercial launch.
  • Preclinical Services Early-phase development services including cell line development, upstream (USP) and downstream (DSP) process development, analytical method development, and pilot-scale manufacturing for non-GMP tox material generation. Supports fed-batch, N-1 perfusion, and full perfusion processes up to Pilot Scale (200L Non-GMP).
  • Clinical Supply Manufacturing Clinical GMP manufacturing services using small-scale asset with 50L, 200L, and 1000L single-use bioreactors. Supports fed-batch, N-1 perfusion, and full perfusion processes for IND, Phase II resupply, and Phase III PPQ.
  • Late Phase and Commercial Manufacturing Commercial GMP manufacturing services leveraging 6x2000L mid-scale asset for scale-up and scale-out production. Supports late-phase clinical through commercial supply with process transfer and PPQ capabilities.
  • Perfusion-Based Bioprocessing Next-generation bioprocessing technology involving continuous exchange of fresh medium for spent medium while retaining cells. Includes N-1 perfusion (intensified fed-batch) and full perfusion. Enables higher cell densities, higher titers, and lower cost of goods per gram with improved sustainability versus stainless steel processes.

Quantifiable outcome

  • Standard Antibody development from Gene to Drug Product in less than 12 months
  • +4 more outcomes

Companies that use CELONIC

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

CELONIC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CELONIC partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and key.

  • CARBOGEN AMCIScoreStrategic or Co-development Partner · 7 October 2025Celonic Group and CARBOGEN AMCIS formed a strategic alliance to offer a fully integrated ADC development and manufacturing solution. The partnership combines Celonic's advanced biologics capabilities (cell line development and antibody production) with CARBOGEN AMCIS's expertise in payload synthesis, conjugation, and sterile fill-finish. This creates a seamless, end-to-end platform for ADC innovators from DNA to drug product. The alliance aims to streamline supply chain, speed up timelines, and support clients from early-stage development through commercial launch.
  • Merck ( Darmstadt, Germany)keyTechnology or Integration · 12 March 2025Celonic Group is integrating Merck's Breez™ micro-bioreactor platform into its process development. The Breez™ 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture system. This addition enhances Celonic's capabilities in monoclonal antibody development and manufacturing by enabling highly efficient, scalable perfusion-based bioprocessing.
  • LINDIS BiotechcoreStrategic or Co-development Partner · 19 February 2025Celonic Group signed a long-term multi-year manufacturing service agreement with LINDIS Biotech for the commercial supply of catumaxomab, a first-in-class trifunctional bispecific monoclonal antibody approved by EMA for treatment of malignant ascites. Celonic will manufacture catumaxomab at its state-of-the-art GMP facility in Heidelberg, Germany.
  • CytivakeyTechnology or Integration · 18 June 2024Celonic's new Biologics Development Center in Basel features Cytiva's Xcellerex XDR single-use bioreactor system. The Xcellerex XDR Bioreactor is a robust and flexible system that can scale from process development to manufacturing scale, enabling customers to reach clinical and commercial milestones faster.
  • RevvitycoreTechnology or Integration · 8 April 2024Celonic signed a commercial license agreement with Revvity for its CHOSOURCE™ expression platform and TnT transposon technology. The Revvity expression platform is used in combination with Celonic's expertise and workflows to enhance cell line development of monoclonal antibodies and complex proteins. Revvity's cGMP manufacturing CHO cell line has over 65 INDs filed globally.

Scale indicators8 records

Recent moves12 records

Expansion highlights6 records

CELONIC competitors and assessment

Company assessment

Direct peers

  • Lonza Group: World's largest pure-play biologics CDMO with end-to-end mammalian and microbial manufacturing services. Direct competitor to Celonic in mAb, bispecific, and biosimilar development and commercial manufacturing; notably, Celonic's CEO Dr. Samanta Cimitan previously led Lonza Group Operations Strategy.
  • AGC Biologics: Global pure-play biologics CDMO with mammalian and microbial capabilities across multiple sites in Europe, U.S., and Asia. Direct competitor offering similar end-to-end services including cell line development, process intensification, and commercial manufacturing.
  • Rentschler Biologics: Privately held European pure-play biologics CDMO headquartered in Germany with similar scale and end-to-end mammalian cell culture services from cell line to commercial supply. Closest comparable in size, ownership structure, and customer focus.
  • WuXi Biologics: Major global biologics CDMO with integrated discovery, development, and manufacturing services across China, Ireland, and the U.S. Direct competitor across the full biologics CDMO value chain.
  • Polpharma Biologics: European-based biologics CDMO with cell line development, process development, and GMP manufacturing for biosimilars and novel biologics. Direct competitor in the mid-sized European biologics CDMO segment; Celonic's CFO previously held a role at Polpharma Biologics.
  • Samsung Biologics: One of the world's largest biologics CDMOs by capacity, operating mega-scale commercial manufacturing plants in South Korea. Direct competitor for large-molecule mAb commercial supply where Celonic's mid-scale asset is structurally sub-scale.
  • Fujifilm Diosynth Biotechnologies: Global biologics CDMO with extensive mammalian and microbial manufacturing capacity across the U.S., U.K., and Denmark. Direct competitor for large-molecule commercial supply and process intensification programs.
  • Boehringer Ingelheim BioXcellence: Biologics CDMO business of Boehringer Ingelheim offering mammalian cell culture contract manufacturing from clinical to commercial supply. Direct competitor in the European biologics CDMO segment with larger commercial capacity.

Broad incumbents

  • Catalent: Large multi-modality CDMO (biologics, cell therapy, oral and injectable fill-finish) recently taken private by Novo Holdings. Broader portfolio than Celonic but overlapping in biologics drug substance and fill-finish — overlapping less on mAb focus but serving similar biopharma clients.
  • Thermo Fisher Scientific (Pharma Services): Diversified life sciences giant with a large contract manufacturing and clinical services business (Patheon). Overlaps with Celonic on biologics development and commercial manufacturing but as part of a much broader portfolio spanning small molecules, clinical research, and lab services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CELONIC social profiles

Digital presence

CELONIC compliance and trust

Trust signal

Compliance1 record

CELONIC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CELONIC leadership team

Management profile

Number of profiles

Profiles7 records

CELONIC subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CELONIC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CELONIC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CELONIC

What does CELONIC do?

Celonic Group is a pure-play Biologics Contract Development and Manufacturing Organization (CDMO) offering end-to-end drug substance development and manufacturing solutions for monoclonal antibodies, bispecifics, and other complex molecules. Services span from cell line development and preclinical process development through clinical GMP manufacturing to late-phase and commercial supply, leveraging proprietary GS-CHOvolution® cell line technology, perfusion-based bioprocessing, and integrated ADC development through strategic alliance with CARBOGEN AMCIS.

Is CELONIC a public or private company?

CELONIC is a private company. It is classified as family owned and is currently operating.

When was CELONIC founded?

CELONIC was founded in 1982. It employs 251 to 500 people.

Where is CELONIC based?

CELONIC is headquartered in Basel, Switzerland, in the Europe region.

How does CELONIC make money?

Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are commercial Manufacturing Supply Agreement.

Who are CELONIC's main competitors?

Direct peers on record are Lonza Group, AGC Biologics, Rentschler Biologics, WuXi Biologics, Polpharma Biologics, Samsung Biologics, Fujifilm Diosynth Biotechnologies and Boehringer Ingelheim BioXcellence. Broad incumbents are Catalent and Thermo Fisher Scientific (Pharma Services).

Does CELONIC have an API?

No public API is recorded for CELONIC.

What industry is CELONIC in?

CELONIC's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologySamanta Cimitan to (re)join Lonza from CelonicSamanta Cimitan will join Lonza as Chief Commercial Officer on 1 January 2027, leading strategic accounts and commercial excellence. She leaves Celonic at the end of 2026, with a successor identified and an announcement expected shortly.GenengnewsCelonic and Leukocare Collaborate to Support Complex Biologics and Advanced Drug DevelopmentCelonic and Leukocare entered a collaboration to support biopharmaceutical companies developing complex biologics, combining Celonic's cell line and process development with Leukocare's data science-driven drug product development. The partnership targets bispecific antibodies, multispecific antibodies, fusion proteins, and high-concentration formulations, aiming to help clients establish development strategies from preclinical through commercialization.European BiotechnologyCelonic’s Strategic Alliance in ADCsThe Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform, combining Celonic's biologics expertise with CARBOGEN AMCIS's payload synthesis and conjugation capabilities for end-to-end ADC solutions. The partnership addresses growing demand in the oncology sector where fragmented supply chains and complex manufacturing requirements create delays and cost pressures for ADC developers. CARBOGEN AMCIS is also investing $32 million to expand its Aarau and Neuland sites by 2027 to support commercial-scale ADC manufacturing capacity.DrugdiscoverynewsCelonic Group and CARBOGEN AMCIS form strategic partnership for integrated ADC developmentCelonic Group and CARBOGEN AMCIS announced a strategic partnership to provide an integrated ADC development and manufacturing platform. The collaboration combines Celonic's biologics expertise with Carbogen AMCIS’s payload and conjugation technologies, aiming to streamline ADC development from research to commercial supply.BenzingaCureVac Taps Celonic For COVID-19 Vaccine ProductionCureVac BV has partnered with Celonic Group to manufacture over 100 million doses of its mRNA-based COVID-19 vaccine candidate CVnCoV at Celonic's facility in Heidelberg, Germany, with more than 50 million doses expected before the end of 2021. The agreement includes technology and knowledge transfer already underway. CureVac reaffirms its broader European manufacturing network capacity of up to 300 million doses in 2021, having previously secured partnerships with Bayer for Phase 2b/3 development and with GlaxoSmithKline for next-generation COVID-19 mRNA vaccines.PR NewswireAirway Therapeutics and Celonic Group Collaborate to Produce AT-100 as Promising New Candidate for CoronavirusAirway Therapeutics and Celonic Group announced a collaboration to produce AT-100 (rhSP-D), a novel human recombinant protein, as a therapeutic candidate against COVID-19. Celonic will handle process optimization and GMP manufacturing for clinical studies, with production expected to begin in June 2020. The companies position AT-100 as potentially lifesaving for seriously ill COVID-19 patients, particularly those in intensive care, until a vaccine becomes available.PR NewswireCelonic AG Partners with Sparta to Improve Quality and Deliver Higher Customer SatisfactionCelonic AG, a Swiss biologics contract development and manufacturing organization based in Basel, has adopted Sparta Systems' TrackWise Digital QMS platform to upgrade its quality management system. The SaaS-based solution will provide Celonic with greater visibility across quality events, employee training management, and remote access capabilities without requiring upfront IT infrastructure investments. Both companies expect the partnership to help Celonic better serve biopharma customers while realizing incremental cost savings.PR NewswireMerck rozbudowuje możliwości upstream firmy Celonic przez instalację bioreaktorów pojedynczego zastosowania Mobius®Firma Merck ogłosiła, że Celonic AG, szwajcarska firma typu CDMO (contract development and manufacturing organization), modernizuje swój zakład produkcyjny w Bazylei poprzez instalację pięciu bioreaktorów pojedynczego zastosowania Mobius® o pojemności 50, 200 i 2000 litrów. Modernizacja rozbuduje możliwości upstream firmy Celonic, zwiększając jej elastyczność i skalowalność w zakresie produkcji biosymili oraz platformy rozwijania linii komórek. Bioreaktory Mobius® firmy Merck mają zapewnić elastyczny, skalowalny system odpowiadający potrzebom zarówno firmy Celonic, jak i jej klientów farmaceutycznych.